43 results about "Proteus vulgaris" patented technology

The invention discloses a longifolene derivative (2, 2, 8, 8-tetramethyl-4-atrane [5. 4. 0. 11, 9] dodecane-6-alkene obtained by rearrangement and reduction reaction and by taking isolongifolene ketoxime as a raw material. Besides, bacteria such as staphylococcus aureus, Klebsiella pneumonia, Escherichia coli, bacillus proteus vulgaris and pseudomonas aeruginosa can be inhibited by the longifolene derivative, and particularly, the longifolene derivative has a superior insecticidal effect on pests such as aphids and rice planthopper.

The invention discloses a method for efficiently preparing micromolecular chondroitin sulfate and micromolecular hyaluronic acid by one step, and belongs to the technical field of bioengineering. According to the method, chondroitin sulfate ABC lyase derived from proteus vulgaris ATCC33420 is heterologously expressed, a signal peptide wapA is selected, and constitutive xylose promoter Pxyl and pHY300PLK vectors are used, and secreted expression of the chondroitin sulfate ABC lyase in bacillus subtilis is realized through induction by xylose; the micromolecular chondroitin sulfate and the micromolecular hyaluronic acid can be produced efficiently and continuously by a designed chondroitin lyase-enzyme membrane reactor. The method has the advantages that the food-grade bacillus subtilis serves as a host strain, and safety and reliability are realized; effective reference is provided for industrial green production of the micromolecular chondroitin sulfate and the micromolecular hyaluronic acid; energy conservation and emission reduction are realized, and economic and social benefits are remarkable.

The invention discloses a kit for detecting clinically common pathogenic bacteria by adopting an RNA isothermal amplification melting curve method and applications of the kit, belonging to the technical field of biological detection. The kit can detect the 16S rRNA of the following 16 clinically common pathogenic bacteria: staphylococcus aureus, pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, proteus mirabilis, enterobacter aerogenes, pseudomonas fluorescens, acinetobacter baumannii, salmonella typhimurium, enterobacter cloacae, enterococcus faecium, enterococcus faecalis, bacillus proteus vulgaris, staphylococcus epidermidis, onion klebsiella and stenotrophomonas maltophilia. The kit has the features of high specificity, high sensitivity, low pollution, and detection accuracy and rapidness, plays an important role in clinical rapid identification and detection analysis of microbes, and has the wide application prospect.

The invention discloses recombinant yeast for fermentation production of chondroitin sulfate with controllable molecular weight and an application of the recombinant yeast, and belongs to the technical field of bioengineering. Pichia pastoris GS115 is used as an original strain by utilizing a synthetic biological technology and a genetic engineering means, and chondroitin sulfate synthetic pathway related proteins including KfoC and KfoA from escherichia coli K4, chondroitin sulfate transferase C4ST or C6ST from mice, UDP-glucose dehydrogenase TuaD from bacillus subtilis and chondroitin sulfate lyase ABCI from proteus vulgaris are heterologously expressed in cells, so that production strains for synthesizing chondroitin sulfate A (CSA) and chondroitin sulfate C (CSC) are obtained, and chondroitin sulfate A and chondroitin sulfate C with specific molecular weights can be obtained by controlling the concentration of an inducer namely methanol and the induction time. According to the recombinant yeast, the chondroitin sulfate with controllable molecular weight and specific configuration is synthesized by utilizing a microbial fermentation carbon source for the first time.

The invention relates to fermentation production and preparation of an active product, belongs to the field of bioengineering and in particular relates to a prodigiosin (PG) producing strain as well as a preparation method and an application thereof. The PG producing strain is Proteus Vulgaris and is preserved on June 24th, 2013 in CGMCC (China General Microbiological Culture Collection Center) and has the preservation number of CGMCCNo.7815 and the preservation unit address of No.3 No.1 Courtyard, West Beichen Road, Chaoyang District, Beijing, Institute of Microbiology of Chinese Academy of Sciences. The PG producing strain can produce PG through fermentation, and an improved inorganic salt culture medium is adopted and is cultured for 18-24 hours at a culture temperature of 20-28 DEG C and a rotating speed of 150-300rpm, and yield of PG can be 80-120mg / L. The produced prodigiosin has an inhibitory activity to staphylococcus aureus, salmonella paratyphi, tritirachium album and pseudomonas aeruginosa and has a good application prospect in bio-preparation of the PG.

The invention discloses a kit for detecting clinically common pathogenic bacteria by adopting an RNA isothermal amplification melting curve method and applications of the kit, belonging to the technical field of biological detection. The kit can detect the 16S rRNA of the following 16 clinically common pathogenic bacteria: staphylococcus aureus, pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, proteus mirabilis, enterobacter aerogenes, pseudomonas fluorescens, acinetobacter baumannii, salmonella typhimurium, enterobacter cloacae, enterococcus faecium, enterococcus faecalis, bacillus proteus vulgaris, staphylococcus epidermidis, onion klebsiella and stenotrophomonas maltophilia. The kit has the features of high specificity, high sensitivity, low pollution, and detection accuracy and rapidness, plays an important role in clinical rapid identification and detection analysis of microbes, and has the wide application prospect.

Disclosed is an effective therapeutic agent for keloid and / or hypertrophic scar. Specifically disclosed are: an elastic fiber-regenerating agent, which comprises chondroitinase ABC derived from Proteus vulgaris; and a therapeutic agent for keloid and / or hypertrophic scar, which comprises the regenerating agent as an active ingredient.

An isolongifolenone oxime ether derivative is prepared by the following steps of: taking isolongifolenone as the raw material, synthesizing isolongifolenone oxime through addition-elimination reaction, and performing alkylation reaction of the isolongifolenone oxime. Simultaneously, the isolongifolenone oxime ether derivative disclosed by the invention can inhibit bacteria, such as staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, bacillus proteus vulgaris and pseudomonas aeruginosa, and fungus, such as Aspergillus niger, exserohilum turcicum, corn sheath blight, alternaria musae Bovr.et Bat. and colletotrichum musae; and the isolongifolenone oxime ether derivative has the excellent insecticidal action for insect pests, such as aphid and rice planthopper.

The invention discloses a strain of Proteus vulgaris derived from human intestinal flora, a new application of its fermented liquid and the components contained therein. The strain, named HA‑3151, is effective against common Gram-positive and Gram-negative pathogens such as Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae, Proteus mirabilis, Escherichia coli, enteritis Salmonella has obvious inhibitory effect. The bacterial strain, its fermented liquid and its components can be used in medicine, food manufacturing and research and development.

The invention discloses antibacterial maca gel and a method for preparing the same. The antibacterial maca gel comprises 0.5-1.0% of maca extract liquid, 1.0-1.5% of cinnamon extracts, 0.1-0.15% of clove extract liquid, 0.1-0.15% of capsicum annuum extract liquid, 0.1-0.5% of cistanche deserticola extracts, 0.10-0.15% of benzalkonium bromide, 2.0-2.5%o of carbomer and the balance water. The antibacterial maca gel and the method have the advantages that antibacterial, inflammation diminishing, itching relieving and anti-fungal effects and the like can be realized by the antibacterial maca gel prepared by the aid of the method, inhibition effects can be realized for hemolytic streptococcus, streptococcus pneumoniae, Escherichia coli bacteria, proteus vulgaris, salmonella paratyphi A, shigella dysenteriae, Escherichia coli, staphylococcus aureus, methicillin-resistant staphylococcus aureus, candida albicans, pseudomonas aeruginosa and the like, the antibacterial maca gel is high in skin compatibility and can become effective fast, and good antibacterial effects can be realized.